The global lipid regulators market size is anticipated to expand at significant CAGR during the forecast period, 2021–2028. The growth of the market is attributed to the increasing patients, growing geriatric population, upsurge in disposable income of people, and growing demand for lipid regulators. Consumer prefers lipid regulators owing to easy availability of the products due to busy and hectic lifestyles.
Lipid regulators are major regulators of cellular function and it is important to maintain the normal function of enzymes, transporters, receptors, and others so that it is localized in membrane. It is important bimolecular that acts as precursor for bile acids and steroid hormones. Lipid in excess quantity is not good for health and body. Lipid metabolites produced by number of enzymes such as lipoxygenases, cyclooxygenases, and others to mediate vital cellular functions. Lipid regulating medications are readily and easily available in retail pharmacies as the general medicines.
Lipid metabolites and fatty acids can also activate the nuclear peroxisome proliferators operated receptors. Lipid molecules are formed by free radical mechanisms that also apply potent biological effects in wide range of organs. Lipid regulators also handle the fragile bones with large susceptibility named Osteoporosis and it also deals with the myocardial infractions called as heart attack along with cholesterol control. Statin and non-statin is more effective rather than individual drugs.
|Report Title||Lipid Regulators Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast|
|Segmentation||Types (Statins [Statin Combinations, Branded Statins, and Generic Statins] and Non-statins [Bile-acid Sequestrants, Fibric-acid Derivatives, Nicotinic acid Derivatives, and Others])|
|Regional Scope||Asia Pacific, North America, Latin America, Europe, and Middle East & Africa|
|Report Coverage||Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast|
|Key Players Covered in the Report||Pfizer; Teva Pharmaceuticals; Abbot Laboratories; Bentley Pharmaceuticals; Novartis; AstraZeneca; Bristol-Myers Squibb; Astellas Pharma; Amgen; and AbbVie Inc.|
Based on types, the global lipid regulators market is bifurcated into statins and non-statins. The statins segment is further segmented into statin combinations, branded statins, and generic statins. The non-statins segment is further segregated into bile-acid sequestrants, fibric-acid derivatives, nicotinic acid derivatives, and others. The statins segment is expected to constitute a key share of the market during the forecast period owing to its effectiveness than any other regulators at lowering cholesterol concentration and rising prevalence of dyslipidemia. Statins also decreases the risk of developing atrial fibrillation. Statins are thought to have non-cholesterol related effects including anti-inflammatory properties, endothelial function, and restoring.
However, the non-statins segment is anticipated to expand at a rapid pace during the forecast period due to as it helps to decrease the LDL- Cholesterol by various therapies such as niacin, acid sequestrants, fibrates, and cholesterol absorption transport inhibitors. Non-satins agents stringent the rate-limiting step in cholesterol biosynthesis by competitively impeding HMG-CoA reducates.
On the basis of regions, the global lipid regulators market is categorized as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. The market of North America is anticipated to expand at an impressive CAGR during the forecast period. The regional market growth can be attributed to high prevalence of diabetes and obesity in the countries such as Mexico and United States. However, being obese and overweight raises the chances of developing common types of diabetes. Due to diabetes, the risk of dyslipidemia is expected to increase. There is well-developed and advances health care system in North America that increase its research and development activities.
The global lipid regulators market has been segmented on the basis of
Key players competing in the global lipid regulators market include Pfizer; Teva Pharmaceuticals; Abbot Laboratories; Bentley Pharmaceuticals; Novartis; AstraZeneca; Bristol-Myers Squibb; Astellas Pharma; Amgen; and AbbVie Inc. Some of these players are engaged in several market strategies such as mergers, acquisitions, partnerships, collaborations, capacity expansion, and product launches to enhance their market shares.
Some other reports from this category!